Assessment of Physiological Vibration Acceleration (Phybrata) Sensor in Diagnosis of Multiple Sclerosis
Globally, Canada has the highest prevalence of Multiple Sclerosis (MS). Diagnosis relies on magnetic resonance imaging (MRI) to monitor lesion development over time in the brain, spinal cord, and optic nerve. Despite its wide utility, MRI is not easily accessible. MRI requires a designated medical facility and expertise? is expensive, and needs to be done repeatedly to diagnose MS.
Early diagnosis and intervention are crucial to minimize the progression and severity of impairments in MS patients. This project will assess the PROTXX “phybrata” wearable neurophysiological sensor as an easier-to-use, lower cost, and more widely accessible solution that has the potential to revolutionize the diagnosis and monitoring of MS. Clinical applications of the phybrata sensor already encompass concussions, stroke, invasive neurosurgeries, Parkinson’s disease, and elderly frailty. Preliminary work using the PROTXX sensor for remote monitoring of MS patients has also indicated potential broader diagnostic utility. The current study will be the first to thoroughly investigate the potential of digital biomarkers derived from phybrata sensor signals to determine lesion locations in MS patients.
Jodie Gawryluk
PROTXX
Life Sciences
Professional, scientific and technical services
University of Victoria
Elevate
